Product menu

Resources for your patients

SHINGRIX Patient Brochure

SHINGRIX Patient Brochure

View
SHINGRIX and Flu Handout

SHINGRIX and Flu Handout

View
Patient Brochure Chinese

Patient Brochure Chinese

View
Shingles Risk Quiz

Shingles Risk Quiz

View
NA

SHINGRIX Appointment Card

View
Patient Brochure Punjabi

Patient Brochure Punjabi

View
90% Efficacy

The efficacy profile of SHINGRIX in adults ≥50 years was studied in two phase III trials with 29,305 patients

Vaccine efficacy profile was studied in subjects ≥50 years old (ZOE-50) and subjects ≥70 years old (ZOE-70).1

Learn more
Patient icon

Meet the patients that are eligible to receive SHINGRIX

Nearly everyone ≥50 years old should be protected against shingles.2

Learn more
Virus icon

What was shown to be the dominant driver of shingles?

Learn about age-related decline in immunity.3

Learn more

References:

  1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.
  2. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. 
    Accessed November 30, 2022.
  3. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1-30.

Trademarks are owned by or licensed to the GSK group of companies.

©2022 GSK Group of Companies or its licensor.

10661 | 06/23